Literature DB >> 2035427

Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States.

J L Anderson1.   

Abstract

The response of patients with chronic severe heart failure to extended infusions (greater than or equal to 48 hours) of milrinone was evaluated in a multicenter, baseline-controlled, phase III efficacy and safety trial in 189 patients in the United States. Milrinone was given as loading and maintenance infusions according to one of four dose regimens. An effective response was defined as greater than or equal to 20% increases in cardiac index or decreases in pulmonary wedge pressure. All loading doses (range, 37.5 to 75 micrograms/kg/10 min) were effective short term, and maximum response occurred at 15 minutes. For the three effective regimens, cardiac index increased initially (at 15 minutes) by 24% to 42%, and pulmonary wedge pressure decreased by 24% to 33%. Systemic vascular resistance was reduced by 15% to 31%. The maximal acute response was effective in 99% of individual patients. During maintenance therapy, effective responses were seen at infusion doses of 0.375, 0.50, and 0.75 micrograms/kg/min, whereas an infusion of 0.25 micrograms/kg/min was ineffective. During 2 days of maintenance therapy, cardiac index remained augmented by 34% to 39% for the low and intermediate doses and by 44% to 73% for the high-dose infusion regimen. Pulmonary wedge pressure decreased an average of 18% on day 1 and 30% on day 2. Systemic vascular resistance was reduced by 20% to 25%, and stroke work index was augmented by 21% to 58%. Symptomatic improvement was common during intravenous milrinone therapy for symptoms of dyspnea (61% response), orthopnea (63%), edema (62%), and fatigue (40%). Improvement occurred more frequently in those with worse baseline functional indexes and in those with greater hemodynamic responses to therapy. Safety and tolerance were exceptionally good for these patients with advanced heart failure.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2035427     DOI: 10.1016/0002-8703(91)90832-3

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  12 in total

Review 1.  Heart failure: Part II.

Authors:  M S Wilkes; H Middlekauff; J R Hoffman
Journal:  West J Med       Date:  1999-06

2.  Advanced heart failure and management strategies.

Authors:  Krishna K Gaddam; Pridhvi Yelamanchili; Yabiz Sedghi; Hector O Ventura
Journal:  Ochsner J       Date:  2009

Review 3.  PDE3 inhibition in dilated cardiomyopathy.

Authors:  Matthew Movsesian; Omar Wever-Pinzon; Fabrice Vandeput
Journal:  Curr Opin Pharmacol       Date:  2011-09-28       Impact factor: 5.547

4.  Age-related differences in phosphodiesterase activity and effects of chronic phosphodiesterase inhibition in idiopathic dilated cardiomyopathy.

Authors:  Stephanie J Nakano; Shelley D Miyamoto; Matthew Movsesian; Penny Nelson; Brian L Stauffer; Carmen C Sucharov
Journal:  Circ Heart Fail       Date:  2014-10-02       Impact factor: 8.790

5.  Effects of concomitant usage of milrinone and catecholamine for weaning from cardiopulmonary bypass.

Authors:  Y Orime; M Shiono; H Hata; S Yagi; S Tsukamoto; S Kimura; S Ohmiya; A Sezai; H Yamada; M Obana; Y Sezai
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-09

Review 6.  Phosphodiesterase inhibition in heart failure.

Authors:  Matthew Movsesian; Josef Stehlik; Fabrice Vandeput; Michael R Bristow
Journal:  Heart Fail Rev       Date:  2008-12-19       Impact factor: 4.214

7.  Postextrasystolic potentiation in patients with ischaemic heart disease: influence of inotropic agents.

Authors:  Y I Zhang; R H Ritchie; J D Horowitz
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

Review 8.  Therapy for acute heart failure syndromes.

Authors:  Sarah M Donlan; Erin Quattromani; Peter S Pang; Mihai Gheorghiade
Journal:  Curr Cardiol Rep       Date:  2009-05       Impact factor: 2.931

9.  Carvedilol induces greater control of β2- than β 1-adrenoceptor-mediated inotropic and lusitropic effects by PDE3, while PDE4 has no effect in human failing myocardium.

Authors:  Peter Molenaar; Torsten Christ; Emanuel Berk; Andreas Engel; Katherine T Gillette; Alejandro Galindo-Tovar; Ursula Ravens; Alberto J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-03-26       Impact factor: 3.000

10.  Differential Response to Heart Failure Medications in Children.

Authors:  Shelley D Miyamoto; Carmen C Sucharov; Kathleen C Woulfe
Journal:  Prog Pediatr Cardiol       Date:  2018-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.